Neurotoxicity following atezolizumab in a patient with tolerated rechallenge*

AbbreviationsAST

aspartate aminotransferasem

CNS

central nervous system

CTL-4

cytotoxic T-lymphocyte antigen-4

EEG

electroencephalography

GGT

gamma-glutamyl transferase

ICIs

immune checkpoint inhibitors

irAEs

immune-related adverse events

MRI

Magnetic Resonance Imaging

nAEs

Neurological immune-related adverse events

NSCLC

non-small-cell lung cancer

PD-1

programmed cell death protein 1

PD-L1

programmed cell death protein 1 ligand

PRES

posterior reversible encephalopathy syndrome

Keywords

Tecentriq

anti-PDL1

Adverse drug reaction

Immune checkpoint inhibitor

Central nervous system

Seizures

© 2023 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

留言 (0)

沒有登入
gif